Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarecycline in Acute Ischemic Stroke After Reperfusion
NCT05836753Phase 2Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- May 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Sarecycline Group with Placebo Group (2 arms). Primary endpoint: Changes of NIHSS score between baseline and at 7 days after randomization. Status: unknown.
02
Drugs
sarecycline
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05836753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836753.